Good morning :)
$
₹
Wave Life Sciences Ltd

Wave Life Sciences Ltd

WVE

NASDAQ
Asset Logo

Wave Life Sciences Ltd

WVE

NASDAQ
$4.501.00% (+0.04)
$
₹
$4.501.00% (+0.04)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $902.5M the stock is ranked 2851

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.99
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.08
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 13 analysts' reports

Buy
12 analysts
Hold
1 analyst
Sell
0 analyst

Analysts expect a +315.46% price upside over the next year

Current Price$4.50
Target Price$18.52

Company Profile

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Peers

Peers

Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
38.21
38.21
1Y Return
52.07%
52.07%
Buy Reco %
77.41
77.41
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
30.85
30.85
1Y Return
51.57%
51.57%
Buy Reco %
45.83
45.83
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.88
115.88
1Y Return
77.47%
77.47%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
20.99
20.99
1Y Return
12.41%
12.41%
Buy Reco %
15.38
15.38
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
24.51
24.51
1Y Return
4.7%
4.7%
Buy Reco %
90.00
90.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Wave Life Sciences Ltd -1.990
Eli Lilly and Company38.2129.351.10
Johnson & Johnson30.857.532.78

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

7.6
-53.8
17.2
-53.1
38.2
-26
2.2
-69.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue12.5319.69-7.6783.749.178.697.6017.2438.242.27
Net Income-31.55-32.92-61.7829.25-46.87-50.46-53.85-53.17-26.08-69.35
Net Profit Margin-251.69%-167.18%804.84%34.92%-510.93%-580.17%-707.83%-308.37%-68.20%-3052.59%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Wave Life Sciences Ltd (WVE) share price today is $4.50 as of September 17, 2026 at 1:30 AM IST. The stock touched a day high of $4.58 and a day low of $4.42.

  2. Wave Life Sciences Ltd stock trades on NASDAQ under the ticker symbol WVE.

  3. Wave Life Sciences Ltd's market capitalization is $902.48M as of September 17, 2026 at 1:30 AM IST.

  4. Wave Life Sciences Ltd's price-to-earnings (P/E) ratio is N/A as of September 16, 2026.

  5. Wave Life Sciences Ltd's price-to-book (P/B) ratio is 1.99 as of September 16, 2026.

  6. Yes, You can buy Wave Life Sciences Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Wave Life Sciences Ltd shares in three steps: 1. Search Wave Life Sciences Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Wave Life Sciences Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Wave Life Sciences Ltd (WVE) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.2197 shares at the current price of $4.50.

Loading...